Dynavax Technologies reported $852.67M in Current Assets for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Adma Biologics ADMA:US $ 174.78M 3.43M
Alexion Pharmaceuticals ALXN:US $ 6452.6M 619.6M
Amgen AMGN:US $ 24380M 5281M
Astrazeneca AZN:US 26.69B 583M
AstraZeneca AZN:LN 26.69B 583M
Biogen BIIB:US $ 7162.3M 21.4M
Biomarin Pharmaceutical BMRN:US $ 2311.57M 46.27M
Bristol Myers Squibb BMY:US $ 31443M 2282M
Chimerix CMRX:US 128.53M 7.72M
Dynavax Technologies DVAX:US $ 852.67M 268.76M
Gilead Sciences GILD:US $ 14200M 275M
Glaxosmithkline GSK:US $ 18254M 688M
Gw Pharmaceuticals GWPH:US $ 718.73M 10.8M
Idera Pharmaceuticals IDRA:US $ 38.3M 5.18M
Minerva Neurosciences NERV:US $ 67.44M 7.79M
Nektar Therapeutics NKTR:US $ 986.14M 70.01M
Neurocrine Biosciences NBIX:US $ 1005.7M 104.4M
Novartis NOVN:VX 26.25B 2.45B
Regeneron Pharmaceuticals REGN:US $ 13775.4M 437.8M
Sarepta Therapeutics SRPT:US $ 2185.31M 79.91M
Vertex Pharmaceuticals VRTX:US $ 8852.54M 395.03M